◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksI › IRON

Disc Medicine Inc. (IRON) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-29

Disc Medicine Inc. (IRON) operates in the BIOTECHNOLOGY industry and is headquartered in Watertown, United States with about 165 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, IRON reported $0M in revenue and ($212M) in net income.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.

Interactive charts & full statements →

IRON Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Total Revenue($12M)$0M$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M$0M
Gross Margin %
Operating Income (EBIT)($269M)($236M)($130M)($91M)($47M)($31M)($34M)
Operating Margin %2247.8%
Net Income($246M)($212M)($109M)($76M)($46M)($36M)($41M)
Net Margin %2052.6%
EBITDA($242M)($208M)($108M)($76M)($47M)($34M)($34M)
Earnings Per Share (EPS)$-6.68$-6.01$-3.96$-3.42$-44.34$-44.88$-27.02
Shares Outstanding (M)39M35M28M22M1M1M2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRON Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$0M$0M($20M)$8M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M$0M$0M
Gross Margin %0.4%-1.1%
Operating Income (EBIT)($65M)($70M)($67M)($68M)($61M)($40M)($35M)($33M)
Operating Margin %336.8%-856.4%
Net Income($60M)($64M)($61M)($62M)($55M)($34M)($29M)($27M)
Net Margin %304.4%-788.4%
EBITDA($58M)($63M)($59M)($61M)($54M)($33M)($13M)($26M)
Earnings Per Share (EPS)$-1.54$-1.65$-1.71$-1.77$-1.58$-1.02$-0.98$-0.89
Shares Outstanding (M)39M38M35M35M35M33M30M30M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRON Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash from Operations (CFO)($198M)($180M)($94M)($73M)($42M)($28M)($33M)
Capital Expenditures (CapEx)$0M$1M$1M$0M$0M$0M$0M
Free Cash Flow (FCF)($198M)($181M)($94M)($74M)($42M)($28M)($33M)
FCF Margin %1649.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRON Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($44M)($62M)($43M)($48M)($48M)($41M)($28M)($17M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$1M$0M$0M
Free Cash Flow (FCF)($44M)($62M)($43M)($48M)($48M)($42M)($28M)($17M)
FCF Margin %217.9%-605.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRON Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Total Assets$735M$807M$497M$368M$200M$92M$8M
Cash & Cash Equivalents$99M$91M$192M$360M$195M$88M$5M
Total Liabilities$91M$67M$53M$23M$24M$157M$30M
Total Debt (Short + Long-Term)$60M$30M$28M$1M$0M$6M$22M
Total Shareholders' Equity$644M$740M$444M$345M$177M($64M)($22M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IRON viewer.

Other Companies in BIOTECHNOLOGY

← IROCAll “I” companiesIRPC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.